Summary: Marc Cerrada-Gimenez, Ph.D. is appointed to Director of R&D Implementation as of October 2020.
Kuopio, FINLAND, Vilnius, LITHUANIA, Forest Park, IL, USA, Marseille, FRANCE, and Shanghai, P.R. CHINA – October 12th, 2020 – Experimentica Ltd., a leader in preclinical ophthalmic drug discovery services, announces today the appointment of Marc Cerrada-Gimenez, Ph.D., to the position of Director of R&D Implementation at the headquarter in Kuopio, Finland.
During the past year five researchers from different Experimentica sites started their PhD programs. The company also acquired significant R&D support from EU for internal R&D projects. As part of this commitment to our in-house R&D activities, we have created a new position of Director of R&D Implementation.
Dr. Giedrius Kalesnykas, President and CEO of Experimentica Ltd., commented: “We are delighted that Marc has accepted this new challenge and transitioning from overseeing sponsored studies to our growing R&D activities across all sites. We are also lucky to retain his leadership in educating our junior team members.”
About Experimentica Ltd.:
Experimentica Ltd. is a global contract research organization (CRO) that specializes in preclinical models of ophthalmic disease. Our world-class scientists and technicians apply a comprehensive set of skills and industry experience to model ocular diseases using multiple experimental platforms, from cell culture-based systems to complex surgical techniques and in vivo models. With R&D laboratory sites in Kuopio, Finland, Vilnius, Lithuania, and Grand Rapids, Michigan, USA, global representation and an industry-leading portfolio, Experimentica Ltd. delivers the highest quality science to assist clients around the globe in advancing their ophthalmic drug discovery and drug development portfolio.
Contact for media enquiries:
Simon Kaja, Ph.D., Chief Scientific Officer and Vice-President, Americas
Phone: +1 (682) 234-4763
Guillaume Demarne, Pharm.D., Director, Business Development
Phone: +33 (0) 7 83 55 69 52